查詢結果分析
相關文獻
- Acute Monoblastic Leukemia in a Child Following Chemotherapy for Neuroblastoma
- Chemoradiation for Olfactory Neuroblastoma
- 兒童神經母細胞瘤之診斷與治療
- 照顧一位罹患神經母細胞瘤第四期病童之護理經驗
- Successful Treatment of a Bulky Seminoma in an Abdominal Undescended Testis: A Case Report
- Kadish Stage C Olfactory Neuroblastoma Successfully Treated by Chemoradiotherapy: Report of Two Cases
- Ifosfamide-Based Chemotherapy for Previously Treated Lung Cancer Patients
- Treatment of Ultra-High Risk Gestational Trophoblastic Disease by an EMA/CE Regimen
- The Experience of Combination of Chemotherapy and Surgery in Treatment of Advanced Nonseminomatous Germ Cell Tumor of the Testis
- Prenatal Diagnosis and Postnatal Management of Fetal Neuroblastoma: Report of Four Cases
頁籤選單縮合
題名 | Acute Monoblastic Leukemia in a Child Following Chemotherapy for Neuroblastoma=一罹患神經母細胞瘤病童在化學治療後發生急性單核球白血病 |
---|---|
作者 | 江東和; 楊兆平; 洪悠紀; | 書刊名 | 臺灣醫學會雜誌 |
卷期 | 98:10 1999.10[民88.10] |
頁次 | 頁688-691 |
分類號 | 415.5515 |
關鍵詞 | 神經母細胞瘤; 化學治療; 急性單核球白血病; Acute monoblastic leukemia; Secondary malignancy; Neuroblastoma; Chemotherapy; |
語文 | 英文(English) |
英文摘要 | The long-term effects of childhood cancer and its therapy are serious problems that deserve attention. One of the most important late effects is the development of secondary malignancy. We encountered a girl with neuroblastoma who developed acute monoblastic leukemia as a secondary malignancy, 32 months after starting treatment for the primary tumor at the age of 4 years and 100 months. For the primary tumor, she had received cyclophosphamide, ifosphamide, etoposide, epirubicin, cisplatin, and vincristine during a period of 20 months; no radiotherapy was given. Cytogenetic analysis of the leukemic cells showed no specific changes, but a rearrangement of the mixed lineage leukemia gene (chromosome 11q23 translocation) was subsequently found by reverse transcription polymerase chain reaction. The survival time after onset of the secondary malignancy was brief. The leukemogenic hazards of cancer treatment should be weighed against their therapeutic benefits. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。